

3 February 2025

Publication pursuant to SFDR - Summary

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

This financial product promotes environmental and social characteristics and qualifies as product in accordance with Article 8(1) of Regulation (EU) 2019/2088.

Capitalised terms used in this document shall have the same meaning ascribed to them in the latest version of the prospectus of the Company (the "Prospectus"), unless the context otherwise requires. This disclosure document is provided in summary form, for more detailed information please see the Prospectus or the document titled "Publication pursuant to SFDR – Details", available on the financial product's webpage on www.Xtrackers.com.

No sustainable investment objective

This financial product promotes environmental or social characteristics, but does not have as its objective sustainable investment.

The financial product commits to partially invest in sustainable investments. Investments that fail to meet DWS' do no significant harm ("DNSH") thresholds will not be considered towards the sustainable investment share of the financial product, which includes, but is not limited to, involvement in harmful business activities, violation of international norms or involvement in very severe controversies, and violation of certain principal adverse indicator thresholds.

As part of the DNSH assessment, the Reference Index of the financial product (as defined below) includes criteria to reduce exposure to or to exclude securities which are negatively aligned with certain principal adverse indicators, as defined in the pre-contractual disclosure for the financial product.

Any securities violating the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights are excluded by the financial product's Reference Index.

Environmental or social characteristics of the financial product

The financial product promotes environmental and social characteristics and qualifies as a financial product subject to Article 8(1) SFDR by tracking the Reference Index (as defined below) which includes environmental and/or social considerations. The financial product holds a portfolio of equity securities that comprises all, or a substantial number of, the securities comprised in the Reference Index. In order to be eligible for inclusion in the Reference Index, companies must be eligible for inclusion in the Parent Index (as defined below) and pass both thematic selection criteria and ESG screening criteria. The thematic selection criteria calculates a relevance score for potential constituents by assessing companies' exposure to business activities associated with the theme. Securities must meet a certain relevance score threshold to be eligible for inclusion. The ESG screening criteria excludes companies from the Parent Index, which: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities; and/or (v) fail to comply with the United Nations Global Compact principles.

Investment strategy

The investment objective of the financial product is to track the performance before fees and expenses of the "Reference Index",

which is the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index. The Reference Index is based on the MSCI ACWI IMI Index (the "Parent Index"). The Parent Index includes large, medium, and small-capitalisation companies across developed and emerging markets globally. Constituents of the Parent Index which are assessed to have high exposure to business activities associated with the theme of technological innovation in the genomic healthcare sector and which meet certain ESG criteria are eligible for inclusion in the Reference Index.

The Reference Index incorporates the ESG characteristics outlined above and described in more detail in the Prospectus. To assess good governance practices of investee companies, the Reference Index excludes companies with very severe controversies (including governance controversies) using the MSCI ESG Controversies data, and companies that have an MSCI ESG Rating (which assesses, amongst other things, how well companies manage governance risks and opportunities) below a certain threshold or do not have an MSCI ESG Rating.

Proportion of investments

This financial product invests at least 90% of its net assets in investments that are aligned with the promoted environmental and social characteristics. Within this category, at least 1% of the financial product's assets qualify as sustainable investments in the sense of article 2(17) SFDR. Up to 10% of the investments are not aligned with these environmental or social characteristics. A more detailed description of the specific asset allocation of this financial product can be found in the Prospectus. Financial derivative instruments may be used for efficient portfolio management purposes as ancillary investments.

Monitoring of environmental or social characteristics

The Reference Index applies the ESG criteria outlined above. DWS performs a regular independent verification of the ESG credentials of the Reference Index, incorporating two key elements: (i) that the composition of the financial product's portfolio is closely aligned with the ESG standards of the Reference Index, and (ii) that the Reference Index is correctly applying the stated ESG criteria.

Investors should note that whilst the financial product and the Reference Index seek to ensure compliance with such criteria at each rebalance or review date, between these reviews or rebalances, securities which no longer meet these criteria may remain included in (i) the Reference Index until they are removed at the subsequent rebalance or review or, (ii) the portfolio of the financial product until it is possible and practicable to divest such positions.

Methodologies

The attainment of the promoted environmental and social characteristics promoted by the financial product is measured using the following sustainability indicators:

- Exposure to Very Severe Controversies
- Exposure to Worst-in-Class Issuers
- Controversial Weapons Involvement
- Tobacco involvement

More details on these sustainability indicators are available in the Prospectus.

Data sources and processing

The Reference Index uses data from various products provided by MSCI ESG Research LLC. These products include MSCI ESG Ratings, MSCI ESG BISR and MSCI ESG Controversies Scores.

Limitations to methodologies and data

The Reference Index's ESG standards limit the number of securities eligible for inclusion in the Reference Index. As a result, the Reference Index, and as such the financial product, may be more concentrated and underperform the market as a whole or underperform other funds screened for environmental, social and governance standards, or which do not screen for such standards.

The Reference Index solely relies on analysis from the Index Administrator or other data providers (as applicable) in relation to sustainability considerations. Neither the Company, nor any of its service providers, makes any representation with respect to the accuracy, reliability, correctness of the sustainability related data or the way that these are implemented.

Due Dilligence

With regards to the selection of any new reference indices for Xtrackers ETFs, DWS will conduct a due diligence process that includes the assessment of sustainability risks, and endeavour to work in conjunction with benchmark providers to embed certain sustainability risks into the construction of new indexes for both new financial products and also reference indexes considered as a potential reference index in case of substitution for an existing financial product. As part of this process, minimum ESG standards will be applied.

Engagement policies

Active engagement with our investee issuers, using proxy voting and engagement to drive change for the benefit of clients is a key part of DWS Group's approach to sustainable investment. DWS applies an Engagement Policy and Corporate Governance & Proxy Voting Policy.

Designated reference benchmark

The financial product has designated the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index as the reference benchmark. Additional information on the Reference Index can be found on <http://www.msci.com>.

Important Information

The MSCI indices are the exclusive property of MSCI Inc. and its subsidiaries (MSCI) and may not be reproduced or extracted and used for any other purpose without MSCI's consent. The fund is not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to the fund or any index on which such fund is based. The MSCI indices are provided without any warranties of any kind.

© DWS Investments UK Limited 2025.